Journal of the neurological sciences

[1] The tolerability and safety profile of eslicarbazepine acetate in neurological disorders.

[2] Navigators’ Behavior Analysis Using Data Mining

[3] Navigators’ Behavior Analysis Using Data Mining

[4] [Post-marketing safety profile of avocado-soybean unsaponifiables].

[5] Post-marketing safety profile of avocado-soybean unsaponifiables

[6] Bezlotoxumab for the prevention of Clostridium difficile infection: a review of current evidence and safety profile

[7] A novel nonlive, adjuvanted herpes zoster subunit vaccine: a report on the emerging clinical data and safety profile

[8] Bezlotoxumab for the prevention of Clostridium difficile infection: a review of current evidence and safety profile

[9] A novel nonlive, adjuvanted herpes zoster subunit vaccine: a report on the emerging clinical data and safety profile

[10] Safety profile and clinical course of patients with insomnia administered suvorexant by initial treatment status in a post-marketing survey.

[11] Salvage Lymph-Node Percutaneous Cryoablation: Safety Profile and Oncologic Outcomes

[12] Safety profile of heterologous serum produced by the Butantan Institute, in São Paulo-SP, Brazil, from 2012 to 2015

[13] Study of the safety profile of raw (Aśodhita) and cow’s urine processed (gomūtra śodhita) tubers of gloriosa superba L. (lāngali) in albino rats

[14] The tolerability and safety profile of eslicarbazepine acetate in neurological disorders.

[15] Safety Profile of Cefprozil

[16] safety profiles of tripterygium wilfordii hook f: a systematic review and meta-analysis

[17] can probiotics improve efficiency and safety profile of triple helicobacter pylori eradication therapy? a prospective randomized study

[18] effects and safety profile of betahistine in patients in the russian contingent of osvald, an open-label observational study in vestibular vertigo

[19] statin therapy and hepatotoxicity: appraisal of the safety profile of atorvastatin in hyperlipidemic patients

[20] Safety Profile of a Cognitively Unimpaired Older Population with Elevated Cerebral Amyloid in a 4.5-Year Clinical Trial.

[21] Clinical Outcomes and Safety Profile of Neoadjuvant PD-1 Inhibitors Combined With VEGFR-TKI Versus VEGFR-TKI in Nonmetastatic Renal Cell Carcinoma.